Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

S1 2020 Earnings Call
Company Participants
FINAL

Denis Kessler, Chairman of the Board of Directors & Chief Executive Officer
Francois de Varenne , Chief Executive Officer of SCOR Global Investments & SCOR
Investment Partners
Frieder Knupling, Group Chief Risk Officer
Ian Kelly, Head of Investor Relations
Jean-Paul Conoscente , Chief Executive Officer of SCOR Global P&C
Mark Kociancic, Chief Financial Officer
Paolo De Martin, Chief Executive Officer of SCOR Global Life

Other Participants
Andrew Ritchie , Analyst
Kamran Hossain, Analyst
Paris Hadjiantonis , Analyst
Thomas Fossard, Analyst
Vikram Gandhi, Analyst

Bloomberg Transcript

Vinit Malhotra, Analyst

Presentation
Operator
Good afternoon, ladies and gentlemen, and welcome to the SCOR Group First Half 2020
Results Conference Call. Today's call is being recorded. There will be an opportunity to
ask a question after the presentation. In order to give all participants a chance to ask
questions, we kindly ask you to limit the number of your questions to two.
At this time, I will now like to hand over to Mr. Ian Kelly, Head of Investor Relations. Please
go ahead, sir.

Ian Kelly

{BIO 19976646 <GO>}

Good afternoon everybody, and welcome to the SCOR Group 2020 First Half Results Call.
I trust everybody is keeping well. I'm joined on the call today by Denis Kessler, Chairman
and CEO of the SCOR Group, and all of the Executive Committee members. Can I please
ask you to consider the disclaimer on Page 2 of the presentation, which indicates that the
financial results for the first half 2020 included in the presentation have been subject to
the completion of a limited review by SCOR's independent auditors. I would also like to
ask you to note the statement in respect of COVID-19, which indicates that the potential
Page 1 of 20



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

impact of the COVID-19 crisis cannot be accurately assessed at this stage given the
uncertainty related to the magnitude and duration of the pandemic and the possible
effects of future governmental actions and/or legal developments.

Bloomberg Transcript

FINAL

With this, I would like to give the floor to Denis Kessler, Chairman and CEO of the SCOR
Group. Over to you, Denis.

Denis Kessler

{BIO 1498477 <GO>}

Thank you very much. Ian, and welcome everybody. If we move to Slide 4. I think SCOR is
demonstrating its capacity to absorb the impact of the CVOID-19 crisis both operationally
and financially. As we entered the pandemic a few months ago and as we told you in the
first quarter of the year, SCOR has been quite proactive in taking immediate actions to
help stop the spread of the pandemic. We have been one of the first reinsurance groups
around the world to say that we had entered a pandemic phase and to warn everyone
about its consequence. We had adopted early and strict prevention measures proactively
protect the health of our employees and we've been quite active in regularly sharing our
knowledge and expertise on the pandemic. I think we are the first reinsurance company to
decide a full confinement around world before any kind of public decision in this respect
so it's for me, certainly a proof of capacity to understand what's going on.
Thanks to the extraordinary resilience of our operational capability, we have been able to
continuously serve our clients during the crisis. And as we have progressed through the
active phase of the pandemic, as you can see on the slide, we have applied moderate
expertise to conduct a thorough several assessment of exposures to the health,
economic, and financial impact of the COVID-19 pandemic. And the industry, as you know,
was one of the first if not the first to say it was an historical shock that will have a long and
very strong impact on the insurance and reinsurance industry, but also to all the industries
that will definitely last longer than expected at the time. On the life side, we have
developed a proprietary what we call SEIR model, which is a compartmental and
epidemiologic model to support the COVID-19 scenario assessment and this model is
extremely useful to estimate exposures.
It's proprietary, it has been homemade, it's really operating, and it helped us a lot in
understanding the consequence of the COVID-19 crisis on life exposures around the
world especially in the US. On the P&C side, we have developed a model that considers
the effect of government and Central Bank measures and links them to the impact on
GDP to estimate the Group credit and surety exposures, certainly what's true in what we
have seen around the last two or three months. Government decisions are absolutely key
to understand the spread of the pandemic. When you confine or you enforce the
decisions you have decided to enforce, when you lift the decisions, and when you
reinforce the decisions again, it's a key parameter to understand how the disease is going
to spread and how severe it's going to be and this is true country by country. And that's
what we have been able today to better assess than a few months ago.
So, there are three key points I would like to make about how SCOR as a Tier 1 reinsurer
comes through this pandemic. The first key point to note is that reinsurance is not
impacted in the same way as most of the businesses. I mean economy (inaudible) and
Page 2 of 20



Bloomberg Transcript

FINAL

Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

look at all the other industries and try to understand how the pandemic is going impact
those industries. And as you have seen and certainly you will see in the future, many
industries have experienced a sharp decline in sales and cash inflows due to the lockdown
and confinement measures that contracted supply and demand on a global scale. The
news flow is strictly coming from the industry not insurance and reinsurance industry, but
from commercial and general industries by the platform is in fact that the pandemic is
contracting the sales activity, creating issues all around the value-added chains. So, this is
not the case for us.
The topline is stable, it's even slightly up compared to last year. A 1% increase of the
worldwide premium holds the entire Group at constant exchange rates and we continue
to collect premiums from our clients and by the way, they pay those premiums and we're
able to book them. As you know, the premium income for some lines of business such as
marine, engineering, and airlines isn't based on economic activity, number of passengers
and so on and so on. But overall, the extraordinary resilience of the Group is
demonstrated by both the P&C and Life business units continuing to expand in the current
crisis. The sales go on. Second key point to emphasize is that the P&C market is clearly
hardening around the world. As a reinsurance business, it is a well-recognized part.
Today's claims are in most cases tomorrow's premiums. As a Tier 1 reinsurer with a AAcredit rating which has been recently confirmed by Moody's, Standard & Poor's, and Fitch;
SCOR is in a very strong position to benefit from this improving market environment.
The third key point as a testimony to SCOR's shock absorbing capacity is that the Group
showed its equity, which accounts for the total estimated cost of the COVID-19 pandemic
booked in Q2, a slightly increase since December 31, 2019, end of last year. The net book
value as a Group stands above EUR34 per share. On the asset side, the unrealized gains
on SCOR's investment portfolio have grown up since the beginning of the year mostly in
the fixed income buckets. Where we are impacted as a reinsurer is on the liability side,
that is why we're here for and so let's take a look at that and move to Slide 5. Let's look at
each business unit separately. SCOR's global P&C exposure comes mainly from credit,
surety, and political risk on the one side and from property business interruption on the
other. The actual CVOID-19 related claims received are limited standing at a total of
EUR74 million.
The Group has estimated the ultimate cost of this pandemic at EUR248 million for P&C
net of retrocession and reinstatement premium and before tax. It is this estimated
amount, which is mostly composed of IBNR, allowing for the future receipts of claims
notified that has been fully booked in the Q2 accounts. This represents a 8.2 percentage
points impact on the year-to-date combined ratio. If we move now on the Life side. The
actual COVID-19 related claims received as at June 30, 2020 are limited standing at a
total of EUR63 million. SCOR has estimated its exposure to the pandemic at June 30,
2020. The Group estimates the impact of the COVID-19 pandemic on its protection grew
at EUR194 million net of retrocession and before tax. It is this estimated amount, I repeat
EUR194 million, which allows estimate of debts incurred, but not reported that has been
fully booked in the Q2 accounts.
What this means is that based on data currently available, on information received from
SEDAR to-date, and the reserves that was used; the total estimated cost for the COVIDPage 3 of 20



FINAL

Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

19 pandemic booked in Q2 2020, which was EUR456 million net of retrocession, net of
reinstatement premiums, and before tax. As such, COVID-19 pandemic is a fully
manageable earnings event for the Group. I said it already a few weeks ago, it's an
earnings event, it's not a capital event. Let's now move to Slide 6 and look at the
Company's position. Solvency position of the Group on June 30, 2020 is strong at 205%,
well within the optimal solvency range of 185% to 220% as defined in the last Quantum
Leap strategic plan. The majority of the fall in this ratio compared to year-end 2019 has in
fact nothing at all to do with the performance of the business of reinsurance. It is mainly
down to macroeconomic impacts, principally the reduction of interest rates and in
particular the US dollar interest rates.

Bloomberg Transcript

These market movements account for approximately two-third of the change in the
solvency ratio. The two-third allocated or imputed to macro financial and macroeconomic
developments. Only one-third that you can attribute to SCOR specific development. The
full estimated COVID-19 impact including claims expected to be incurred in the future
accounts for 13 points of solvency. This is more than offset by the strong operating
performance of the Group and so was a minor effect across H1 2020. Capital
management as shown on the slide accounts for 6 percentage points of movement. It
reflects the intended call in Q4 of the CHF125 million debt and it also accounts for the
normal six month accrual of dividend for the 2020 fiscal year. Let's move to Slide 7. In the
face of the COVID-19 pandemic, SCOR once again demonstrates both its capacity to
absorb major shocks and the resilience of its business model.
SCOR has strong potential for sustained long-term value creation in an attractive industry.
(inaudible) benefits from long-term growth drivers due on the first hand to the expanding
risk universe as we can sequence permanent growth of the industries raw material. And
on the other side, there's a progressive bridging of the protection gap in both emerging
markets and more industrialized countries. Furthermore, we do expect that as a direct
result of the pandemic, there will be an increase in risk aversion linked to (inaudible)
driving higher demand for risk covers globally on both the Life side and the P&C side. In
the P&C market, we see COVID-19 acting as an additional catalyst for the really hardening
market. The firming up of the market has accelerated since the April renewals across
many segments with broad improvements in terms of conditions and significant price
increases including the claims free programs.
Further, the awareness of the upward trend of claims cost has increased in the market.
These conditions are perfect for SCOR to benefit from its Q1 figures. The Group can see
market opportunities through leveraging its global franchise, marketwide expertise, and
Tier 1 rating; and through gaining operational leverage from its scalable global
underwriting platform. With this positive outlook I would like to underline and to stress.
I will now hand over to Mark to take you through the H1 financials, Mark, the floor is yours.

Mark Kociancic

{BIO 17852409 <GO>}

Thank you, Denis, and good afternoon everyone. So, let's go to Slide 9. During the first
half of 2020, SCOR successfully absorbed the impact of COVID-19 combining this with
resilient growth and strong solvency. SCOR wrote EUR8.2 billion euros of gross written
Page 4 of 20



Bloomberg Transcript

FINAL

Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

premium during the first half representing a 1% increase over H1 2019 at constant
exchange rates or 2.3% at current exchange rates. The ability of the reinsurance sector
and SCOR to maintain its topline is a real source of strength for the Group demonstrating
the resilience of the business model in the current environment. After absorbing the
COVID-19 impacts, the Group remains profitable and net income stands at EUR26 million,
which translates into a return of just under 1%. The solvency position of the Group is
strong and stands at 205% at the end of the half year, in the upper part of the optimal
range of our solvency scale of 185% to 220%.
The reduction compared to the 31st of December 2019 is largely driven by market
movements, as Denis explained, and the 5 points reduction since the Q1 results release
can be largely explained by accounting for the planned call of the CHF125 million Swiss
debt in the fourth quarter later this year. And this also includes the normal six months
accrual for the dividend for fiscal year 2020. Let's look at the business unit indicators in
more detail. SCOR Global P&C grew strongly at 0.9% at constant exchange rates or 2.1%
at current exchange rates. The combined ratio stands at 102.3% for the first half
incorporating the impact of COVID-19 at 8.2 percentage points. The business unit benefits
from slightly reduced nat cat activity with a cat ratio at 5.1% for the first half of the year and
an underlying combined ratio at 96% in line with the Quantum Leap assumption.
SCOR Global Life continues to successfully expand its franchise and delivered a positive
set of results for the first half of 2020. SCOR Global Life gross written premiums also
proved resilient to the current circumstances and were up 1% at constant exchange rates
and up 2.5% at current exchange rates. The Life technical margin is at 5.4% reflecting a
cost of 4.6%, COVID impact and benefits from portfolio management actions, and a
strong reserving position. SCOR Global Investments pursues a prudent asset
management strategy and enjoyed a strong return on invested assets of 2.6% in the first
half of 2020 benefiting from real estate capital gains. So, let's move on to Slide 10. The
balance sheet is another source of strength for the Group with shareholders' equity
standing strong at EUR6.4 billion in the first half of 2020, even slightly up compared with
the 31st of December 2019 and this is a testament to the ability of the Group to absorb
the COVID-19 pandemic.
This results in a strong book value of EUR34.19 per share. Financial leverage is in a solid
place and stands at 25.9%. Allowing for the debt callable in the fourth quarter of 2020,
the adjusted financial leverage stands at 24.9%. On Page 11, we can see that SCOR
generated strong operating cash flows in the first half standing at EUR343 million in Q1
2020 with good contributions from both business units. Overall, the total liquidity of the
Group is very strong and stood at EUR2.8 billion at the end of the first half.
With this, I will hand over to Jean-Paul who will provide further detail on SCOR Global P&C.

Jean-Paul Conoscente

{BIO 20770277 <GO>}

Thank you, Mark. If I take you to Slide 12. As stated previously, this quarter's results have
been heavily impacted by the cost of COVID-19. We have conducted an in-depth review
of our exposures to the COVID-19 outbreak and the following government mandated
orders to flatten the curve of the spread of the virus. Our assessment represents our
Page 5 of 20



FINAL

Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

ultimate view of our exposures giving the information currently available both in terms of
premiums and claims. It should be noted that this is still an ongoing event and that to-date
little information has been received from our clients. As of the end of Q2, we have
processed EUR74 million of claims gross of retrocession mostly from affirmative nondamage business interruption reinsurance claims. The COVID-19 ultimate claims impact in
Q2 is estimated at EUR248 million pretax net of retrocession and premium
reinstatements. This represents an impact of 8.2 points on the year-to-date net combined
ratio.
The main drivers of the claims are credit and surety and property lines of business with
limited exposure coming from other lines of business. We have also booked the
anticipated ultimate drop in premium income from economically sensitive lines of
business including aviation, credit and surety, and engineering. The anticipated premium
reduction is roughly EUR100 million or roughly 3% of the premium volume for the first half
of the year. Our half year results -- if we move to Slide 13. Our half year results were also
impacted by a number of small cat events including several tornadoes in the US and
hailstorms in New South Wales and Calgary. We also saw an increased frequency of small
to medium size man-made events.

Bloomberg Transcript

Other market events such as US riots were immaterial to our results. As mentioned by
Mark, we had a net combined ratio of 102.3% for the first half of the year.
Normalized of the impact of COVID-19 and of cat, our net combined ratio stands at 96%
in line with the Quantum Leap assumptions. Our premium volume is increasing year-onyear by roughly 1% at constant rate of exchange, including the impact of COVID-19
showing the resilience of our portfolio. We move to Slide 14. For the P&C markets, we see
COVID-19 as an accelerator of the market hardening observed in 2019 and '20. This was
confirmed in the treaty renewals since April and illustrated once again in the June and July
renewals. Whilst the market hardening is the most pronounced on property and property
cat renewals globally, it is also expanding to all lines of business and most geographies. It
is reflected not only in price increases, but also in changes in terms and conditions. SCOR
Global P&C is ideally positioned as a global Tier 1 multiline reinsurer to take advantage of
this market turn as illustrated by 8.2 points of price increases achieved in our June and
July renewals.
We achieved double-digit premium growth across segments and geographies where
profitability improvements were the most strongest. We also continue to review the rest
of our portfolio adjusting our participations as a function of our view of loss costs versus
price increases achieved. Our overall treaty premium renewed at the June and July 1st
renewals increased year-over-year by 1.3% despite a significant projected premium
decrease year-on-year from lines of business directly affected by COVID-19. If we move
to Slide 15. We have also continued to seize opportunities in specialty insurance in a
disciplined way. Specialty insurance remains a strong growth and profit generator for
Global P&C as illustrated in the first half of the year 2020 results and we grew our
portfolio year-on-year by 20% in the first half on the back of a total rate change of 22%
across the different lines of business.

Page 6 of 20



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

FINAL

In summary, with the impact of COVID-19 being manageable for SCOR, we are very
bullish on the P&C prospects for the remainder of 2020 and 2021. We believe the hard
market will be durable as it is based on a combination of factors that are unlikely to
dissipate any time soon. And through its global scalable platforms and strong client and
broker relationships, SCOR Global P&C is ideally positioned to benefit from this durable
market turn.
I will now pass the floor to Paolo.

Paolo De Martin

{BIO 15930577 <GO>}

Bloomberg Transcript

Thank you, Jean-Paul. COVID-19 is a tragic event with a dramatic loss of life and livelihood.
Although we are discussing today the financial impact, we cannot lose sight of the
traumatic impact it has had and continues to have on individuals and families across the
world. I would like to stress how the situation is still evolving and all estimates we're
presenting heavily rely on expert judgment and they are subject to a high degree of
uncertainty. We view the pandemic as having three phases. An entry phase in the
pandemic world where the virus takes a foothold in our environment and establishes
sustained transmission. Intensity of the impact of the virus is most severe during this
phase due to lack of knowledge and delayed mitigating action. This is followed by an
active phase where we are cohabiting with the virus. The active phase is a balancing act
between keeping economic activity open and avoiding moving back into an exponential
growth of the epidemic.
All of this while seeking incremental improvements from control measures and medical
treatment. Our view is that we have now entered the active phase and at this point, we
estimate we will remain in the active phase for the next 12 months or longer. Our current
assumption is that once a safe and effective vaccine is made available for wide inoculation
and large part of the populations will reach immunity, we will gradually accelerate into the
post-pandemic world and this will represent the exit phase. We consider the entry phase
to have covered the period going from March to June 2020. In terms of the financial
impact on the SCOR -- on the portfolio of SCOR Global Life, we expect that the entry
phase will have the highest relative cost and therefore, we assume a lower burn rate from
COVID-19 related claims going forward.
In Q2 2020 we have booked COVID-19 related claims of EUR194 million net of retro and
pretax. Due to typical claim reporting patterns, limited COVID-19 claims were reported
during Q2 and most of this amount represent estimates of incurred claims. This impact
includes EUR182 million of claims incurred in the US with the balance coming from other
markets. The COVID-19 claims costs impacted negatively the year-to-date technical
margin by 4.6 percentage points. Our overall technical profitability benefited from active
portfolio management and strong reserving position leading to a year-to-date net
technical margin for the first six months of 5.4%. This result demonstrates the resilience of
the SCOR Global Life business. Moving on to Page 17 of the presentation, few words on
the US COVID-19 related claims.
The estimated impact of COVID-19 related debt on our US book reflects strong
differences between the general US population and our reinsured portfolio and
Page 7 of 20



FINAL

Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

particularly this is driven by the upfront medical underwriting, higher socioeconomic
classes which we believe is particularly relevant during this pandemic environment, and
the lower portion of older lives in our portfolio. The provision recorded in Q2 heavily relies
on expert judgment. Just to remind all on the call, the reporting of each month of that
takes an average of six calendar months to fully complete. So by the end of Q4 2020, we
will have a clearer view on the claims incurred during the entry phase. Moving on to Page
18 of the presentation, we would like to share our thoughts on how we look at the time
ahead of us. Overall, while significant uncertainty remains and the situation is evolving
particularly in the US, we believe that the impact of the active phase on our Life portfolio
will be manageable.
We're currently projecting that our technical margin will land at between 5.2% to 5.4% for
the full-year 2020, which means that the business will still generate over EUR400 million
of pre-tax technical profitability for the year. As mentioned at the beginning of my speech,
significant uncertainty remains and we are following the situation very closely with a large
focus on epidemiological research. Before I close my section, few words on the business.
We have continued to support our clients globally throughout this challenging time. While
activity has been impacted by the pandemic and the lockdowns, we expect our premiums
to remain stable at 2019 level for the full-year 2020. I will leave more details on our views
and the evolving COVID-19 pandemic for today to the Q&A and we will update you on our
evolving thinking in September at Investor Day.
I will now hand it over to Francois for details on our Investment performance.

Bloomberg Transcript

Francois de Varenne

{BIO 7447858 <GO>}

Thank you, Paolo. Moving on to the Investment portfolio. The asset allocation reflects the
current environment and our cautious positioning. Liquidity stands temporarily at 13% of
invested assets, up from 6% at the end of '19 and 11% at the end of the previous quarter.
The share of corporate bonds is stable compared to last quarter at 41%, our lowest level
since 2017. And the fixed income portfolio remains of very high quality with a stable
average rating of A+, a duration of 3.1 year, and highly liquid with financial cash flows over
the next 24 months reaching EUR8.7 billion expecting to emerge from the Investment
portfolio. Our return on invested assets stand at 2.6% since the beginning of the year. It
benefits from real estate capital gains of EUR48 million coming from the disposal of a
building at very good conditions in the first quarter of 2020 just before the COVID-19
outbreak.
Additional capital gain we are generating out of the fixed income portfolio and loans
portfolio for a total EUR14 [ph] million. This relates to risk mitigation actions that we have
voluntarily undertaken since the beginning of the year. Our theoretical reinvestment yield
excluding future capital gains stand at 1.5% at the end of June and reflects the lower
interest rate environment notably in the US as well as the normalization of credit markets.
Moving on to Page 20. I first would like to highlight that SCOR invested assets portfolio
has demonstrated its resilience and shock absorbing capacity thanks to a moderate risk
appetite for investment risk, the risking action undertaken since 2019, and also the
integration of sustainability into our investment process. As indicated last quarter, our

Page 8 of 20



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

FINAL

portfolio has a limited exposure to sectors directly affected by the current crisis and a very
limited exposure to equities.
It is well positioned to face a further deterioration of economic and financial condition. In
particular, the emergence of a credit crisis should be manageable both in terms of
potential future impairments and in terms of credit transition risk. Faced with the
pandemic outbreak, we have decided in March 2020 to voluntarily freeze our investment
activity and to build up liquidity in order to savor the value of our assets. In a less volatile
environment, we have decided to resume our investment activity in June. We are coming
back to credit markets, but this will be done very progressively and cautiously while strictly
sticking to our risk management.
With this, I will hand it over to Ian Kelly for the conclusion of the presentation.

Ian Kelly

{BIO 19976646 <GO>}

Thank you very much. Francois. On Page 21, you will find the forthcoming scheduled events
starting with our Investor Day to be held on September the 9th. This will be a virtual event
and we will send further details on this soon.
With that, we can now move to the Q&A session. And can I remind you to please limit
yourself to two questions each. Thank you.

Bloomberg Transcript

Questions And Answers
Operator
(Operator Instructions) Our first question is coming from Kamran Hossain from RBC.
Please go ahead, your line is open.

Q - Kamran Hossain

{BIO 17666412 <GO>}

Hi. Thanks for taking my questions. The first one is just around the capital position and
dividends. From the way I understand it, you accrue two quarters of dividend in there.
Obviously launches wasn't paid, but you have the potential to do it. What's the thinking
around catch-up and then I guess in your solvency position, have you assumed any catchup or kind of -- from last year? So, that's the first question. I appreciate you might not be
able to answer that fully. And the second question is just thinking about 1/1, it kind of sits
on the things, I think it should be positive, but Europe has been relatively soft or difficult to
kind of see rate improvement in the last few years. What does that take? So, is this the
kind of BI impacts in Europe or just any thoughts around that on why kind of the wider
global reinsurance market should move at 1/1? Thank you.

A - Ian Kelly

{BIO 19976646 <GO>}

Maybe Mark, you can pick up on capital and dividend view first of all.

Page 9 of 20



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

FINAL

A - Mark Kociancic

{BIO 17852409 <GO>}

Yes, sure. Hi, Kamran. So, what I would reference you to Slide 6 of the investor pack that
might help the discussion. So, we've tried to be very clear on this slide with capital
management not to mention the COVID impact, operating performance, and
macroeconomic impacts on solvency. So with respect to dividends, you've seen the ACPR
come out and essentially forbid dividends in 2019. So, what we've done is we've added
back the 2019 fiscal year dividend and that represents approximately 7 percentage points
of solvency. You'll recall I think in the last meeting, I referenced the fact that you can only
declare a dividend for 2019 through September 30th of the following year. So September
30, 2020 and thereafter, it can be done; but it would have to be done as a special
dividend or something else.
So for 2019, we don't see a dividend -- sorry, for 2020, we don't see a dividend being
declared and paid this year given what's transpired from a regulatory framework. We have
taken the normal step of accruing our quarterly dividend -- regular dividend in the
solvency slide for fiscal year 2020 and I think what will happen is we will review the capital
position of the Group in February like we normally do and apply our capital management
policy which is unchanged to determine what the level of dividend will be in 2021. And I
would remind you that that's a Board decision that will take place. I will also point out that
we do have a strong FTP capital position. I think the solvency position even at 205% is in a
good spot for us. So, I think there are positives as well that we bring from a capital
perspective.

Q - Kamran Hossain

{BIO 17666412 <GO>}

Bloomberg Transcript

Thanks, Mark.

A - Ian Kelly

{BIO 19976646 <GO>}

Thank you, Mark. Jean-Paul, if you could pick up on the 1/1 renewals and in particular the
European context.

A - Jean-Paul Conoscente

{BIO 20770277 <GO>}

Thank you, Ian. I think the comment on Europe has been fair. When we look at the 1/1
renewal 2020 in Europe, the rate increases we saw were more moderate but they were
still positive probably more in the 2% to 3% in Europe. If we take the July renewal, which is
of course a much smaller renewal for Europe than July 1st, we see significant differences.
Overall, the European renewal in July saw price increases of more than 6% and if we
focus on non-proportional treaty, which represents the bulk of the treaty business we
have in Europe, we saw a rate -- reinsurance rate movements of plus almost 11%. So, we
think that the -- it's not just the expected claims coming from non-damage BI in Europe
that's driving this. It's also the -- just the overall environment. And we believe that the
June, July renewals is a good illustration of what we can expect at January 1st, 2021. So,
the rest of the markets (multiple speaker) we saw very strong movements in the US and
July 1st is mainly an Asia renewal and Australia where we saw also strong price
movements.

Q - Kamran Hossain

{BIO 17666412 <GO>}
Page 10 of 20



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

Okay. It sounds very encouraging. Thanks very much.

A - Ian Kelly

{BIO 19976646 <GO>}

FINAL

Thanks, Kamran. The next question, please.

Operator
Our next question is coming from Andrew Ritchie from Autonomous. Please go ahead,
your line is open.

Q - Andrew Ritchie

{BIO 18731996 <GO>}

Bloomberg Transcript

Hi there. Thanks a lot for the additional detail you've talked about on Life today. I wonder
if it -- Paolo and maybe Mark, could you just talk a bit more around Slide 18. I'm trying to
understand -- I think what you're trying to illustrate is that you've taken an IFRS hit, you've
disclosed and talked about that. But then you talk about the Solvency II impact which -where you've assumed a further hit than what's in IFRS I think, it's like you're receiving an
additional 125,000. What was the kind of reasoning behind it or how have you come up
with? Why is there a difference? Is this because in Solvency II you can sort of reflect future
expected profit or lack of profits? Just maybe a bit of color around that would be very
useful. I think it's a very important slide. The second question, year-to-date rate -- renewal
rate increase on the P&C side I think is 4%. Maybe could you just help us translate what
that would mean in terms of margin? I take it, it will take time to be earned, I understand
that; but just on the discrete accident year. Is all that rate is going to be margin or what
should be the kind of loss cost offset?

A - Ian Kelly

{BIO 19976646 <GO>}

Okay. So on the first part on the Solvency II impact, Paolo.

A - Paolo De Martin

{BIO 15930577 <GO>}

Yes. Hi Andrew. In our IFRS accounts incurred our key accounting event so in each
reporting period, we estimate the amount of debt incurred in that specific reporting
period and our estimate usually relies on reported claims, past experience, and expert
judgment. And as you well know, Andrew, our IFRS accounts following the current
accounting rules under IFRS 4 do not reflect the full value of future cash flows coming
from our Life portfolio and these cash flows in our accounting processes create a strong
level of prudence in our liability adequacy testing for our reserves. Under Solvency II, the
full estimated value of our future cash flow is considering our solvency ratio and therefore
when accounting for COVID-19 claims impact, we need to include the forward-looking
provision.
So, the way we came up with that provision. We have a relatively comprehensive scenario
planning right now that roll forward for 12 months. That scenario based planning is based
on level of infection rates and level of fatality rate for the virus and then we apply a
probability weighted on the scenarios. When we looked at that, we come up with 175,000
deaths for the next 12 months. As a good rule, about two-third that we expect to happen
in 2020 and one-third of those in 2021. We expect the infection in terms of death toll at
Page 11 of 20



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

this point according to our scenario planning and our research to reduce as we approach
mid-year 2021. We will present more details about this at the Investor Day where we can
update you on the Q3 and we'll give you an update on the 12-month roll forward as well.
(multiple speakers)

FINAL

Q - Andrew Ritchie

{BIO 18731996 <GO>}

Yes. So, I think that in practical terms that means that the Solvency II position of the Life
business is kind of depressed or at least what would happen is you will generate capital in
the Life business. To the extent that capital is depressed by COVID claims, those COVID
claims have already been up to the point you've reflected -- already being reflected?

A - Paolo De Martin

{BIO 15930577 <GO>}

Exactly. Under Solvency II, we have gone to ultimate effectively.

Q - Andrew Ritchie

{BIO 18731996 <GO>}

Got it. Okay. That's very clear. Thank you.

A - Paolo De Martin

{BIO 15930577 <GO>}

Ultimate of claims not incurred yet so it is subject to a very high level of uncertainty.

Q - Andrew Ritchie

{BIO 18731996 <GO>}

Bloomberg Transcript

Yes, I got it.

A - Ian Kelly

{BIO 19976646 <GO>}

Okay. Thanks. And then, Jean-Paul, on the year-to-date rates experienced in the renewals.

A - Jean-Paul Conoscente

{BIO 20770277 <GO>}

Yes. So the year-to-date as you stated, we saw roughly 3 points of price improvement in - at January 1st, roughly 5 points at April, and now a little bit more than 8 points in June,
July with an average of 4 points for the first half. We think this translates into an
improvement in margin between 1 point to 1.5 points and this should be -- start to be
reflected in our accounts as we earn premium over the next two quarters.

Q - Andrew Ritchie

{BIO 18731996 <GO>}

Great. Thank you.

A - Ian Kelly

{BIO 19976646 <GO>}

Thanks very much, Andrew. We'll go to the next question.

Operator

Page 12 of 20



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

Our next question is coming from Vikram Gandhi from Societe Generale. Please go
ahead.

FINAL

Q - Vikram Gandhi

{BIO 18019785 <GO>}

Hi. I hope you can hear me alright. Vikram, SocGen. I've got two questions. Firstly, can you
please confirm if the 13 percentage point COVID-19 impact in Solvency II ratio includes
exactly the same figure as in IFRS for P&C claims, that's the EUR248 million number? The
reason I'm asking this is I can't reconcile the 13 percentage point with the EUR392 million
on the Life side that's included in the Solvency II so presumably there's some degree of
variance on the P&C side. That's question one. Secondly, can you also comment on what
benefits, if any, you are assuming from the Group's longevity exposure against your
mortality claims? Thank you.

A - Ian Kelly

{BIO 19976646 <GO>}

Thanks, Vik. So Frieder, if you can pick up on the Solvency II impacts.

A - Frieder Knupling

{BIO 17247809 <GO>}

Bloomberg Transcript

So hi, everybody. The 13 point -- percentage points estimate includes all the claims
estimates for Life and P&C up to the ultimates which we have discussed earlier. It also
includes a few secondary effects, some SCR movement, slight increases, and some tax
effect. So, that's why you probably can't reconcile them fully. But we will come back to this
at the Investor Day when we are hopefully able to update the estimates and then maybe
we can help with that reconciliation.

A - Ian Kelly

{BIO 19976646 <GO>}

Thanks, Frieder. And Paolo, if you can pick up the longevity offset.

A - Paolo De Martin

{BIO 15930577 <GO>}

Yes. Hi Vikram. We expect the longevity to give us a good edge economically, particularly
against our UK mortality book. On IFRS, given the way the longevity business earns, we're
not seeing much of a benefit on IFRS 4, but we're seeing a good benefit from an
economic perspective.

Q - Vikram Gandhi

{BIO 18019785 <GO>}

So, is that impact already reflected in the Solvency II ratio economic effect?

A - Paolo De Martin

{BIO 15930577 <GO>}

That economic effect currently is not reflected in the Solvency II ratio, but we would
expect that to be offset by claims coming from our UK mortality portfolio, which are also
not reflected in the Solvency II number. So, they offset each other. So, you wouldn't see a
big upside coming from that.

Q - Vikram Gandhi

{BIO 18019785 <GO>}

Page 13 of 20



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

Okay. Thank you.

A - Ian Kelly

{BIO 19976646 <GO>}

FINAL

Thanks very much, Vik. The next question please.

Operator
Our next question is coming from Vinit Malhotra from Mediobanca. Please go ahead, your
line is open.

Q - Vinit Malhotra

{BIO 16184491 <GO>}

Bloomberg Transcript

Yes. Good afternoon, everybody. So, my two questions. The first one would just be on the
P&C growth, which I appreciate you're quite pleased with. But I would just -- I mean if you
look at the US for example when I see the 1% growth in the US, just a bit curious as to
what lines are you holding back in. And I know from speaking to the IR team today that
there was a quota share or some quota shares that you didn't participate. But then if
there's any more commentary around where you're holding back in casualty or whatever
you'd like to comment. So -- and second thing is just on the asset re-risking. So the 1.5%
reinvestment yield on Slide 19, is that assuming that some of the re-risking is already in
place or would you say that there were other measures you would take to kind of
increase that? And also one comment I would -- when I see the 2Q versus 1Q pie chart,
liquidity only 2% move; but listening to you on the call in the 1Q, it felt like there was quite
a bit of a change on how much cash is being held. So, I'm just curious on where you are on
the re-risking and how to look at this needle going forward. Thank you.

A - Ian Kelly

{BIO 19976646 <GO>}

Thanks, Vinit. So Jean-Paul, first of all on the P&C US growth.

A - Jean-Paul Conoscente

{BIO 20770277 <GO>}

Yes. Thank you, Ian. So, you're right that June and July we -- our overall US book has
shown a slight decrease. It's driven by two factors. First, it's the area of this renewal. We
have some significant renewals in credit and surety as well as in auto. We have one -especially one treaty on auto that is around the mobility business and both of those lines
of business were heavily impacted in terms of the projections -- or ceding to our
projections in 2020 year-on-year is a significant drop. So, that element on its own
represents roughly 4 points of overall premium year-on-year for all Global P&C. The
second portion is the continued re-underwriting of the -- of our portfolio especially on
casualty. We remain very attentive to the increase of loss costs from social inflation and
other factors, including the potential impact of COVID-19. And so even if price increases
are sizable, sometimes they don't offset in our view the increase of loss cost. And so if
that's the case, then we take actions on managing our shares on those treaties. So, what
you see on the US book is a combination of both. But what we also outlined is you see a
strong growth on the property side where we believe the price increases are positive and
above the loss cost and there on the cat for example, we grew our book by double-digits
on US cat.

Page 14 of 20



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

Q - Vinit Malhotra

{BIO 16184491 <GO>}

Okay. Thank you.

A - Ian Kelly

{BIO 19976646 <GO>}

FINAL

Thank you, Vinit. Let's take the next question, please.

A - Francois de Varenne

{BIO 7447858 <GO>}

No. Maybe -- yes, maybe.

A - Ian Kelly

{BIO 19976646 <GO>}

I'm sorry.

A - Francois de Varenne

{BIO 7447858 <GO>}

To the question on, Ian...

A - Ian Kelly

{BIO 19976646 <GO>}

Apologies, Francois. Go ahead.

Bloomberg Transcript

A - Francois de Varenne

{BIO 7447858 <GO>}

Yes. Two points. So, the first one on the reinvestment rate. Again I insist on the definition
of -- that we use for many years now on the definition of the reinvestment rate. That's the
theoretical reinvestment rate at which we should deploy EUR1 or $1 in the portfolio with
the same allocation -- asset allocation at the end of the quarter. So in practice, that's the
market yield of the portfolio. So, if we deploy to the -- at the end of June $1 or EUR1 in the
portfolio again with the same asset allocation which mean in practice with the same
amount of liquidity, this euro will generate on an average 1.5%. So, that's not linked to the
historical reinvestment rate during the quarter and we have been consistent with this
definition over the last few years. So, your second question is where we are reinvesting
and what is the amount of liquidity accumulated over the last few quarters.
So, again we have deliberately decided to put our investment activity on hold since the
beginning of March and we have kept all financial cash flows emerging from the
investment portfolio in cash in practice between early March and mid-June. So further to
this decision that was explained to protect and to safeguard the value of our investment
portfolio during the peak of the volatility on the market, our liquidity exposure stands at
13% at the end of Q1 compared with 11% at the end of -- stand at 13%, sorry, at the end of
Q2 compared to 11% at the end of Q1 since again we have accumulated cash between
March and June and this amount was 6% at the end of December last year. So as I
mentioned it, we have decided to resume our investment strategy in June. This will be
done very cautiously and progressively during the second half of 2020 of course market
condition allowing.
So hence, our investment activity in Q2 was almost immaterial. So, where are we are
reinvesting today? With less volatile financial market and after the freeze of the
Page 15 of 20



FINAL

Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

reinvestment activity between March and June, we have decided to launch a investment
program market condition allowing that will aim at cautiously and progressively increase of
corporate bond exposure. The current level is 41%. We target by the end of Q3 or Q4,
again depending on market condition, to come back to a level of 45%. So, this program
focuses mostly on increasing the recurring financial contribution of the invested asset
portfolio and we will avoid the riskier sectors; namely energy, automotive, hotel, and
leisure; and we are targeting mostly primary issuances to capture if possible additional
premium on the market.

Q - Vinit Malhotra

{BIO 16184491 <GO>}

Okay. Thank you.

A - Ian Kelly

{BIO 19976646 <GO>}

Thank you very much. We can go to the next question now. Thanks.

Operator
The next question is coming from Paris Hadjiantonis from Exane Paribas. Please go ahead.

Bloomberg Transcript

Q - Paris Hadjiantonis

{BIO 19703051 <GO>}

Yes. Hi everyone from my side as well. I hope you're doing well. I'm looking at Slide 16 so I
guess it's a question for Paolo. When I look at the technical margin for the first half and I
normalized for the COVID impact, that is at a very, very high level of about 10%. I assume
there's probably some release of prudence, but if you can give us some more clarity,
Paolo, of why the underlying looks pretty good in the first half of the year. The second
question relates to your contingent capital facility of EUR300 million that you have with JP
Morgan. One of the triggers of that is the ultimate net claims amount for Life Insurance.
So, I was wondering if you can give us some more color of where we stand versus the
trigger point right now, I think you have to see two consecutive six month periods of
elevated claims. But any kind of clarity on that front will be certainly useful. And also if you
can remind us how exactly it works, whether it's in different tranches, et cetera. Thank you.

A - Ian Kelly

{BIO 19976646 <GO>}

So Paolo, first of all on the technical margin.

A - Paolo De Martin

{BIO 15930577 <GO>}

Yes. Very good. On the technical margin, I'd like to remember that we have a large book
of business and we've been -- over the years been very active in managing our in-force
and this has given us over time some margin of flexibility in managing shocks and this has
been very helpful in the situation and will offer us some further flexibility going forward. In
addition, as you said, we are benefiting from a strong reserving position built throughout
the years. And I have to say that all these factors are considered also on the projections
that we gave you on the full-year 2020. In terms of the contingent capital, we're not far
away from triggering the contingent capital. We're going to give a thorough update on all

Page 16 of 20



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

our field capital as we go to Investor Day. So if you wait till Investor Day, we'll give a good
update there.

Q - Paris Hadjiantonis

{BIO 19703051 <GO>}

FINAL

Sorry, Paolo. I didn't get you said you are far away or not far away.

A - Paolo De Martin

{BIO 15930577 <GO>}

Yes, we are far away.

Q - Paris Hadjiantonis

{BIO 19703051 <GO>}

Okay.

A - Paolo De Martin

{BIO 15930577 <GO>}

Yes. We are far away from triggering it, yes.

Q - Paris Hadjiantonis

{BIO 19703051 <GO>}

Clear. Thank you.

A - Ian Kelly

{BIO 19976646 <GO>}

Bloomberg Transcript

Thanks very much. Paris. And I think we can take the next question.

Operator
Certainly. Our next question is coming from Thomas Fossard from HSBC. Please go
ahead, your line is open.

Q - Thomas Fossard

{BIO 1941215 <GO>}

Yes. Good afternoon. Just two questions. The first one would be on the Life side, just to
better understand. I think that remembering the initial discussion we had on the Life book
at the start of the year, I think that you clearly mentioned that there were huge -- kind of a
huge or significant symmetry between the profile of the people dying from COVID-19 and
your insured book. And as long as the mortality was pretty strong in Europe, I would say
that this kind of symmetry was working pretty well. But it seems to be that we see the
virus going into the US, this symmetry maybe less perfect or it seems to be that -- I mean
to be fair, the amount of losses -- mortality losses you're reporting today on the US and
maybe also on the next 12 months is potentially somewhat of a surprise in terms of
magnitude of the losses. So, I was wondering if you could help us to better understand
why this is the case and why this is the case and why we've got such a number.
And also a small add-on is on your scenario of additional 175 million -- sorry 175,000
deaths. Why would it be I would say it kind of linear -- (inaudible) in linear in terms of claims
estimates. It's a kind of doubling of the losses, would have expected it to be I would say
more impactful for your earnings as long as -- as soon as the number of deaths on a
Page 17 of 20



FINAL

Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

cumulative basis would increase to higher level. And the second question will be related
to the P&C segment. You're currently trading with a significant discount to book and there
is a view in the market that SCOR has less leeway, less gearing to improving market
conditions and this is where you're trading with a discount. Can you reassure that at this
point in time you've got the full capacity to take the advantage of improving market
conditions with your -- with currently your financial mean and that there is no need or no
intention to come to the market to raise money to put additional capital at work? Thank
you.

A - Ian Kelly

{BIO 19976646 <GO>}

So first of all, Paolo, for you on the Life side.

A - Paolo De Martin

{BIO 15930577 <GO>}

Bloomberg Transcript

Yes, Thomas. No, the symmetry is still very -- I mean there is still a very strong difference
between general population and insured population. The only reason why you're seeing
more claims in the US compared to Europe where we had very little impact is one,
Europe, our book is very focused on younger ages and very connected to credit as well.
And we're not seeing losses coming through, their face amounts are much smaller. The
US is just that we have a much larger book that we have in Europe. If you recall all the
Investor Days, I think you can recognize that we had about -- we had a number about 15
million in terms of the people that we ultimately reinsure in our portfolio. If you take an
overall US population of 327 million, that gives you like roughly around 4.5%. So, it is the
size that makes the claims maybe larger as you see them.
We still believe there is a very strong difference between the general population and the
insured population driven, as I said, by the upfront medical underwriting, by
socioeconomics which play extremely strongly in this pandemic. If you just take the
significant amount of death that in the US that happen in retirement homes where most
of the people are actually been officially on Medicaid and those people are largely not
likely to are -- to be in possession of a life insurance policy. And the third point is our book
is much younger than the general population in the US. Just give you a sense, the general
population is about 13 million of people over 8 years older so that's about 4% I guess and
in our case, about 1.5% of our book is above -- is over 8 years old. So, we still see a very
large difference between the two books. And Thomas, could you repeat your second
question? I don't think I fully understood it. You had two questions on the Life. The second
question wasn't very clear. Hello.

A - Ian Kelly

{BIO 19976646 <GO>}

I think your line is till muted, Thomas.

Operator
Mr. Fossard, your line is open.

Q - Thomas Fossard

{BIO 1941215 <GO>}

Page 18 of 20



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

FINAL

Sorry I'm back. I was -- the second question was on the first 163,000 deaths, you incurred
roughly EUR200 million and for an additional 175,000, you're going to incur another
EUR200 million. So, it seems that there is a kind of perfect linearity in terms of claims
impact as a proportion of the total number of deaths. And potentially I would have
expected at some stage maybe I would say the losses to be more important just because
you could have some kind of excess of loss contracts starting to kick in or something like
that. It seems to be very linear or...

A - Paolo De Martin

{BIO 15930577 <GO>}

Yes, it is linear. Keep in mind that we don't have in this case the structures that you might
imagine in a P&C book. We cover per life amounts to our clients. There is a difference
between as and insured portfolios because we -- our clients retain a certain amount per
life and we have very little first loss business and we see almost our entire lives at excess
8 million. So we have an 8 million retention that we apply, but we don't have accumulation
on excess of loss structures. It is a per life and is relatively linear. So, roughly you have
about EUR10 million, EUR11 million per 10,000 deaths at this point. That average may
change significantly as the geography of the epidemic changes and our portfolio is now
evenly distributed through the States. But as a rule of thumb for the moment given all the
uncertainty we have, that provides you a decent rule of thumb.

Q - Thomas Fossard

{BIO 1941215 <GO>}

Okay. Thank you, Paolo.

Bloomberg Transcript

A - Ian Kelly

{BIO 19976646 <GO>}

Thanks. Paolo. And then finally, Mark, if you can pick up on the Group capacity.

A - Mark Kociancic

{BIO 17852409 <GO>}

Yes. Thanks, Thomas. So, let me just make a few points here and perhaps Jean-Paul can
finish the commentary for the question. So to start with capacity, I think it's important to
establish the fact that we do have a very scalable platform in P&C. So there's nothing
internally that needs to be built; structurally referrals, underwriters, et cetera, pricing
actuaries, to increase volume substantially if we wanted to. We have prepared over the
years for this type of moment. So, I think the structure is there. In terms of the capacity so
like I said before, we do come into 2020 with a strong S&P capital position. We also think
the solvency position is relatively strong. I don't see any kind of equity raise in 2020. It -I'm not sure it makes sense given where we are with the pricing anyways. There could be
potentially a limited debt issuance, small; but that could be something that supports
additional organic growth particularly in a P&C hard market. I think you'll see us
emphasizing our message going forward of how we take the opportunities provided by
the COVID crisis during our IR Day in September. So, there could be some hybrid issuance
limited to facilitate additional capital for a larger expansion, but otherwise I think we're
pretty much set.

A - Jean-Paul Conoscente

{BIO 20770277 <GO>}

And just to complete what Mark said, we have already at the June, July renewals taken
the opportunity when we thought the business was attractive to increase our shares. And
Page 19 of 20



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2020-07-23

as we look for plan 2021, we'll have the same approach so push for larger shares on
business that we think is providing value to the Company and where we think the -- again
the price increases outpaces the loss cost increases.

Q - Thomas Fossard

{BIO 1941215 <GO>}

FINAL

Okay. Thank you.

A - Ian Kelly

{BIO 19976646 <GO>}

Thank you very much. Thomas. That was the final question so we'll close the Q&A there.
I'd just like to say thank you very much to everybody for attending this conference call.
And as usual, the IR team's on hand to pick up on any further questions you may have. So,
please don't hesitate to give us a call should you require any further information. So with
that, keep well and I would like to wish you all a good day.

Operator

Bloomberg Transcript

This does conclude today's call. Thank you for your participation. Ladies and gentlemen,
you may now disconnect.

This transcript may not be 100 percent accurate and may contain misspellings and other
inaccuracies. This transcript is provided "as is", without express or implied warranties of
any kind. Bloomberg retains all rights to this transcript and provides it solely for your
personal, non-commercial use. Bloomberg, its suppliers and third-party agents shall
have no liability for errors in this transcript or for lost profits, losses, or direct, indirect,
incidental, consequential, special or punitive damages in connection with the
furnishing, performance or use of such transcript. Neither the information nor any
opinion expressed in this transcript constitutes a solicitation of the purchase or sale of
securities or commodities. Any opinion expressed in the transcript does not necessarily
reflect the views of Bloomberg LP.  COPYRIGHT 2022, BLOOMBERG LP. All rights
reserved. Any reproduction, redistribution or retransmission is expressly prohibited.

Page 20 of 20

